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Background: Triptolide is a therapeutic diterpenoid derived from the Chinese herb Tripterygium wilfordii Hook f.
Triptolide has been shown to induce apoptosis by activation of pro-apoptotic proteins, inhibiting NFkB and c-KIT
pathways, suppressing the Jak2 transcription, activating MAPK8/JNK signaling and modulating the heat shock responses.
Results: In the present study, we used lymphoblast cell lines (LCLs) derived from 55 unrelated Caucasian subjects to
identify genetic markers predictive of cellular sensitivity to triptolide using genome wide association study. Our results
identified SNPs on chromosome 2 associated with triptolide IC50 (p < 0.0001). This region included biologically interesting
genes as CFLAR, PPIl3, Caspase 8/10, NFkB and STAT6. Identification of a splicing-SNP rs10190751, which regulates CFLAR
alternatively spliced isoforms predictive of the triptolide cytotoxicity suggests its role in triptolides action. Our results from
functional studies in Panc-1 cell lines further demonstrate potential role of CFLAR in triptolide toxicity. Analysis of
gene-expression with cytotoxicity identified JAK1 expression to be a significant predictor of triptolide sensitivity.
Conclusions: Overall out results identified genetic factors associated with triptolide chemo-sensitivity thereby opening
up opportunities to better understand its mechanism of action as well as utilize these biomarkers to
predict therapeutic response in patients.
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Triptolide is a biological diterpenoid derived from the
Chinese herb Tripterygium wilfordii HOOK f. Triptolide
has been shown to have anti-inflammatory and immuno-
suppressive activities and has been used in traditional
Chinese medicine to treat several diseases, such as,
rheumatoid arthritis, immune complex diseases, and sys-
temic lupus erythematosus [1, 2]. It has been shown to
have influence on several anti-tumor target genes and
inhibit tumors by altering multiple signaling pathways,
such as, inhibition of NFκB and c-KIT pathway [3], in-
hibition of Jak2 transcription [4], inducing apoptotic* Correspondence: jlamba@cop.ufl.edu
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(http://creativecommons.org/publicdomain/zerosignals by activation of pro-apoptotic proteins [5, 6], ac-
tivation of MAPK8/JNK [5, 6], and inhibition of heat
shock response [7, 8]. Triptolide has also been shown to
influence epigenetic modulation of genes by interaction
with histone methyltransferase and demethylase [9]. In
spite of the wide therapeutic properties of triptolide,
poor water solubility has limited its clinical use in the
past. However, recently a water-soluble analog of tripto-
lide–Minnelide has shown promising results in pancre-
atic cancer cell lines, human xenograft models, as well
as in mouse models of pancreatic cancer [10]. Minnelide
has been shown to reduce tumor burden in preclinical
models of osteosarcoma [11]. Taken together with the
anti-tumor properties of triptolide and the recent devel-
opment of triptolide analogs to overcome its waterarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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tumor agent.
In the present study, we evaluated the impact of gen-
etic variations and gene expression profiles predictive of
triptolide cytotoxicity using Epstein-Barr-virus trans-
formed lymphoblastoid cell lines (LCLs) that are part of
International HapMap project (www.hapMap.org) [12].
HapMap LCLs has been used as model to identify gen-
etic markers associated with in vitro chemo-sensitivity
to several drugs [13–16]. Genotype data is publically
available allowing for genome-wide association analyses
for biomarker identification. Our results validated some
of the known genes/pathways as well as identified novel
candidate genes/pathways of relevance to triptolide. We
further validated the functional significance of CFLAR in
pancreatic cell lines.
Methods
In vitro cytotoxicity assays
HapMap LCLs from subjects with European ancestry
(CEU; n = 55 unrelated) were obtained from the Coriell
Institute for Medical Research and were maintained as
recommended. In vitro cytotoxicity was determined by
treating LCLs with varying concentrations of triptolide
(500, 50, 20, 10, 6.67,1.3 and 0 nM) for 48 hr followed
by cell viability measurements using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays (Life Technologies, USA) and Synergy 5 multi-
plate reader. Cytotoxicity assays were performed in du-
plicates and cell lines were randomly chosen to repeat
on different dates to rule out any experimental variation.
Panc-1, a pancreatic cell line (ATCC, USA) was used for
functional validation of the top gene identified in the
GWAS. Panc-1 was cultured in DMEM medium supple-
mented with 2 mM glutamine and 10 % fetal bovine serum.
Real-time quantitative PCR analysis
mRNA expression levels of CFLAR spliced isoforms were
quantitated in LCLs and Panc-1 cell lines using CFLAR
isoform specific oligonucleotide primers and 2^-ΔΔCT
method as described in Additional file 1 and Fig. 2.
Genotyping of panc-1 cell lines
Genomic DNA from Panc-1 cell line was genotyped for
CFLAR SNP rs10190751 (A/G) using TaqMan SNP geno-
typing assay (Applied Biosystems, Foster City, CA, USA).
Genomic DNAs from HapMap cell lines with known
genotype (AA, AG and GG) were used as controls.
Western blotting
Western plotting was performed using whole-cell lysates
and CFLAR (Enzo lifesciences) or β-actin (Abcam) pri-
mary and mouse IgG secondary antibodies.siRNA mediated knockdown of CFLAR in cancer cell lines
Mission esiRNA were procured from Sigma Aldrich.
esiRNA were synthesized through in vitro transcription
of a 300–600 bp gene specific dsRNA, which is further
digested in to complex pool of siRNA using RNAses.
This digested pools of esiRNA are verified by DNA
sequensing and gel electrophoresis to ensure identity
and high specificity (Sigma Aldrich). To ensure high spe-
cificity and efficacy of the esiRNA, the algorithm DEQOR
is utilized (Design and Quality Control of RNAi, available
to the public via http://deqor.mpi-cbg.de/deqor_new/
input.html). CFLAR specific 424 base pair sequence used
in this study to create esiRNA pool for CFLAR knock-













Panc-1 cells were transfected with 200 nM CFLAR-
esiRNA and negative siRNA using Lipofectamine® 2000
(Life technologies) as per manufacturer’s protocol.
Twenty-four hours post-transfections cell were treated
with varying concentrations of triptolide and cell viabil-
ity was determined 48 hr post-treatment using MTT as-
says. mRNA levels of all three isoforms of CFLAR
siRNA were quantitated 24 hr post-transfection to check
for the knockdown.
Transfection of CFLAR-Short and CFLAR-Long plasmid in
Panc-1 cell line
Panc-1 cells were transfected with control and CFLAR
expression plasmids (pEF6-V5, pEF-Flag A, pEF6-V5-
CFLAR-S and pEF-Flag A-CFLAR-L) using Fugene HD
reagent (Promega) followed by triptolide treatment and
MTT assay as described above. Cell pellets were also col-
lected for protein analysis.
Statistical analysis
As these cell lines are part of several publically available
genotyping databases, genotype data was retrieved on
all cell lines from the HapMap project (release 23). For
29 samples, data was also retrieved from the 1000 ge-
nomes project (20101123 version). mRNA expression
was retrieved for all of the individuals from a publically
available source (http://www.sanger.ac.uk/research/areas/
humangenetics/). IC50, concentration that kills 50 % of the
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using the package drc v2.2.1 in R v2.14.0 [17].
Association analysis of triptolide cytotoxicity with genetic
variation
SNP genotype (n = 4098136) data was retrieved from the
HapMap (release 23) for all 55 samples (29 female and
26 male). SNPs were filtered using various quality con-
trol criteria as, build changes, call rate, compliance with
Hardy Weinberg and minimum allele frequency (MAF)
as described in Additional file 1. In total 1978803 SNPs
in 55 individuals passed quality control measures. For
genotype data for individuals in the 1000 genomes only
a MAF filter was used, dropping SNPs with MAF < 0.05.
Several SNPs overlap between the 1000 genomes and
HapMap data, data obtained from the 1000 genomes
project was used preferentially over data obtained from
the HapMap. Since not all of the samples used have
been sequenced as part of the 1000 genomes project as
of current, SNPs in the 1000 genomes project, but not
in HapMap (release 23) were imputed for samples not
included in the 1000 genomes project. BEAGLE v3.3.1
[18] was used to impute SNPs with the reference of the
1000 genomes as described in Additional file 1.
Association analysis of triptolide cytotoxicity with gene
expression variation
mRNA expression from the Illumina Sentrix Human-6
Expression BeadChip version 1 was normalized as per
Stranger et al., using 47293 probes [19]. For this analysis,
only the Caucasian samples were used and data was nor-
malized using quantile normalization across replicates
and median normalization across individuals. Original
Illumina annotation was retrieved from ReMOAT [20].
Expression was not adjusted for gender (did not appear
to affect association with phenotypes).
Integrative analyses
With the wealth of data produced by current genomic
technologies, collection of multiple types of genomic
data on a set of samples is becoming commonplace.
New methods explore a multifactor approach that com-
bine different kinds of genomic data, sometimes referred
to as “integrative genomics” or “genomic convergence”,
in which a multistep procedure is used to identify poten-
tial key drivers of complex traits that integrate DNA
variation and gene expression data. To integrate the
genotype, expression and drug cytotoxicity data, we first
identified markers associated with triptolide IC50 using a
liberal significance threshold of 0.001. Next, we deter-
mined which expression probe sets were associated with
these IC50 associated SNPs (p-values ≤ 10
−5) (i.e., eQTLs).
Finally, to determine whether the expression probe sets
associated with these SNPs were also associated withtriptolide IC50 values, we identified which expression
probe sets were associated with IC50 with a p-values ≤
0.0001). A similar integrative analysis approach has been
used successfully to detect novel candidate genes [21].
The association between IC50 and SNP genotypes mod-
eled as count of rare alleles (additive genetic model), or
log2 normalized mRNA expression and cytotoxicity phe-
notypes, or SNPs was quantified using a spearman correl-
ation coefficient, and p-value calculated for the null
hypothesis of no association using an F-test.
Results
Genetic associations with triptolide IC50 in LCLs
We evaluated 55 LCLs derived from unrelated subjects
with Caucasian ancestry for cellular sensitivity to tripto-
lide. Triptolide IC50 values ranged from 4 to 34 nM
indicating wide inter-individual variation in chemo-
sensitivity. GWAS analysis identified 140 SNPs in 11
genes that were associated with triptolide IC50 at p < 10
−5
(488 SNPs at p < 10−4; Fig. 1a). Significant proportion of
SNPs (110 of 140: 78.6 %) clustered in ~293 kb region on
chromosome 2 (Table 1), which maps to multiple biologic-
ally interesting genes (Genes important for cell division
and Cancer development) including CFLAR, CLK1,
FAM126B, NDUFB3, NIF3L1, ORC2 and PPIL 3 (Table 2;
Fig. 1b). Other genes with significant SNPs included
TP53BP2 (chr 1), MTSU2 (chr 13), ZNF532 (chr18) and
FNDC3B (chr 3). Ingenuity pathway analysis of these
genes mapped them to 4 networks (Table 3). These net-
works are involved in Cellular Movement, Inflammatory
Response, Cell-To-Cell Signaling and Interaction; Cell
Death and Survival, Cellular Function and Maintenance,
Molecular Transport; Cancer, Dermatological Diseases
and Conditions, Developmental Disorder; Cellular Move-
ment, Hematological System Development and Function,
Immune Cell Trafficking and carbohydrate metabolism.
CFLAR (Caspase 8 and FADD like apoptosis regulator)
with maximum number of most significant SNPs (n = 41;
due to high LD as shown in Additional file 2: Figure S1)
codes for protein c-FLIP. c-FLIP regulates apoptosis and is
structurally similar to caspase-8, however, lacks the caspase
activity. It has been implicated as a crucial link between
cell survival and cell death pathways in mammalian cells.
Gene expression associations with triptolide IC50 in LCLs
Genome-wide gene expression analysis identified 14 probes
that were associated with triptolide IC50 (p < 0.0001,
Additional file 3: Figure S2 and Table 4). Some of the
biologically interesting genes with expression levels
associated with triptolide sensitivity included: JAK1
(Janus kinase 1), DTX1 (Deltex Homolog 1; positive
regulator of Notch signaling pathway), AGL (Amylo-
Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase involved
in glycogen degradation), and MUC15 (Mucin 15, Cell
Fig. 1 Genome-wide association study of SNPs with Triptolide cytotoxicity. a Manhattan plot showing association of SNPs with Triptolide IC50
(only SNPs with p <10−4 are included). b Genomic region on Chr 2 with strongest association with triptolide cytotoxicity. Y-axis represents -Log 10
(P value) and X-axis presents chromosomal location
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pathway analysis tool mapped these genes to JAK/
STAT, IL, iNOS, EGFsignalining pathways (Additional
file 4: Figure S3).
Integrated SNP-mRNA association analysis with IC50
We performed integrated analysis between SNPs-mRNA
expression-IC50; we selected top SNPs that were signifi-
cantly (p < 0.001) associated with cytotoxicity, and top gene
expression signatures significantly (p < 0.001) associated
with cytotoxicity for association with each other i.e. SNP
vs. gene expression. This analysis basically identifiedeQTLs associated with triptolide IC50 and at p <0.0001
we identified 648 unique SNP-mRNA pairs that were
associated with triptolide cytotoxicity however these
SNP-mRNA pairs mapped to only 28 genes (Table 5),
indicating association of multiple SNPs with one gene
(which might be due to LD between SNPs). Some of
the biologically interesting SNP-mRNA pairs included:
association of multiple SNPs in chromosome 16 span-
ning genes CHST5, TMEM231, GABARAPL2 and
ADAT1 with expression levels of AGL; SNPs in ASXL3
with ASCL4 expression; CAMTA1 SNPs and CRYGS ex-
pression; TIAM1 SNPs with DTX1 expression; SNPs in
Table 1 List of top 140 SNPs (p <0.00001) from GWAS analysis that were predictive of triptolide cytotoxicity in HapMap LCLs
SNP Position Minor Allele MAF r.ic50 p value Chr Gene_function_list
rs6759004 202004676 C 0.15 −0.63 2.51E-07 2 CFLAR/intron
rs10931931 201994540 C 0.15 −0.62 3.66E-07 2 CFLAR/UTR-5
rs13413479 202012578 G 0.15 −0.62 3.66E-07 2 CFLAR/intron
rs73045343 202017408 G 0.15 −0.62 3.66E-07 2 CFLAR/intron
rs6712963 201982693 G 0.15 −0.62 3.78E-07 2 CFLAR/intron
rs10469755 201917938 T 0.17 −0.62 4.43E-07 2 FAM126B/intron
rs13059218 26910495 A 0.24 0.62 5.11E-07 3
rs73045306 202000395 C 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs6759216 202004710 G 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs10203550 202009586 G 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs13426823 202015677 G 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs12105811 202016245 A 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs73045341 202016550 G 0.17 −0.61 6.01E-07 2 CFLAR/intron
rs111315781 201738724 T 0.14 −0.61 6.27E-07 2 PPIL3/intron
rs73439953 56602702 T 0.33 −0.61 7.51E-07 18 ZNF532/intron
c2.201734921.b37p0 201734921 G 0.14 −0.61 9.19E-07 2
rs55953858 201997292 G 0.21 −0.60 1.66E-06 2 CFLAR/intron
rs4035022 201744352 A 0.15 −0.59 1.76E-06 2 PPIL3/intron
rs3851973 201732878 G 0.14 −0.59 1.79E-06 2 PPIL3/UTR-5 and CLK1/UTR-3
rs111976464 201735042 C 0.14 −0.59 1.79E-06 2 PPIL3/UTR-5 and CLK1/UTR-3
rs11892119 201736112 C 0.14 −0.59 1.79E-06 2 PPIL3/UTR-3
rs7562391 201736166 C 0.14 −0.59 1.79E-06 2 PPIL3/missense
rs7560613 202003010 C 0.21 −0.60 1.83E-06 2 CFLAR/intron
rs6747253 201748415 A 0.15 −0.59 2.17E-06 2 PPIL3/intron
rs73043383 201968246 C 0.17 −0.59 2.19E-06 2 CFLAR/UTR-5
rs7591472 201889751 C 0.17 −0.59 2.20E-06 2 FAM126B/intron
rs10194347 201942480 A 0.17 −0.59 2.42E-06 2 NDUFB3/intron
rs28405687 201906661 T 0.23 −0.59 2.52E-06 2 FAM126B/intron
rs915650 37657526 A 0.38 −0.59 2.54E-06 8
rs7583529 201988238 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs6728771 201992407 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs6706980 201993688 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs58886660 201999283 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs28636431 201999550 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs7573256 202003170 G 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs113350756 202003767 G 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs10190751 202006096 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs56160734 202006860 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs4487072 202008298 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs1981726 202008700 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs7573529 202010626 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs13387186 202012068 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs13413075 202012363 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs12104442 202013956 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
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(Continued)
rs12721505 202014238 G 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs7571899 202015028 G 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs7585993 202015114 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs61289882 202015250 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs68044560 202017080 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs56863085 202017647 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs719125 202017860 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs56009967 202019094 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs56161269 202019210 A 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs2041766 202021495 T 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs4482462 202021747 C 0.21 −0.59 2.57E-06 2 CFLAR/intron
rs75518195 65067404 G 0.36 0.58 2.80E-06 4 nearest gene (~150 kb down TECRL)
rs13384245 201760937 G 0.17 −0.58 2.89E-06 2 NIF3L1/intron
rs10204787 201762147 A 0.17 −0.58 2.89E-06 2 NIF3L1/intron
rs113388793 201771341 G 0.17 −0.58 2.89E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs2307358 201785657 T 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs2307362 201785837 A 0.17 −0.58 2.89E-06 2 ORC2/cds-synon
rs4622700 201793113 T 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs9288314 201794173 T 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs10185727 201803711 G 0.17 −0.58 2.89E-06 2 ORC2/intron
rs13408964 201804972 T 0.17 −0.58 2.89E-06 2 ORC2/intron
rs16836160 201813830 G 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs13429609 201816257 T 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs13392371 201816421 A 0.17 −0.58 2.89E-06 2 ORC2/Intron
rs16836477 201853457 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs6719992 201871978 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs13405753 201881677 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs10197103 201885293 T 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs13384791 201911164 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs13417843 201913429 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs10207746 201916418 C 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs73043345 201920060 G 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs13389349 201920618 C 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs6737556 201924078 T 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs7590522 201924788 T 0.17 −0.58 2.89E-06 2 FAM126B/intron
rs10194168 201942437 T 0.17 −0.58 2.89E-06 2 NDUFB3/intron
rs10205971 201958201 G 0.17 −0.58 2.89E-06 2 NDUFB3/UTR-5 and CFLAR/UTR-5
rs2110728 201965678 A 0.17 −0.58 2.89E-06 2 CFLAR/UTR-5
rs13421776 201760902 G 0.19 −0.58 3.33E-06 2 NIF3L1/intron
rs4381763 201776988 G 0.19 −0.58 3.33E-06 2 ORC2/intron
rs10183261 201797676 A 0.19 −0.58 3.33E-06 2 ORC2/intron
rs10205561 201809704 T 0.19 −0.58 3.33E-06 2 ORC2/Intron
rs2307357 201824092 A 0.19 −0.58 3.33E-06 2 ORC2/Intron
rs3087357 201828365 G 0.19 −0.58 3.33E-06 2 ORC2/UTR-5
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rs874358 201829602 G 0.19 −0.58 3.33E-06 2 ORC2/UTR-5
rs3900738 201863803 A 0.19 −0.58 3.33E-06 2 FAM126B/intron
rs16836568 201879948 G 0.19 −0.58 3.33E-06 2 FAM126B/intron
rs13416500 201771798 A 0.18 −0.58 3.63E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs13404596 201771801 T 0.19 −0.58 3.63E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs6757272 201728141 A 0.35 −0.58 4.14E-06 2 CLK1/intron
rs10184098 202004190 G 0.21 −0.57 4.45E-06 2 CFLAR/intron
rs28447044 64903606 T 0.46 0.57 4.69E-06 4 nearest gene (250 kb down TECRL)
rs11660954 56603803 G 0.26 −0.57 5.27E-06 18 ZNF532/intron
rs34044649 155655693 T 0.42 −0.57 5.59E-06 7
c14.20107162.b37p0 20107162 C 0.24 0.73 5.84E-06 14
rs2950160 4420188 G 0.31 −0.57 5.96E-06 8 CSMD1/intron
c18.56609415.b37p0 56609415 T 0.24 −0.57 6.60E-06 18
rs9854411 171921569 C 0.16 −0.57 6.70E-06 3 FNDC3B/intron
rs13412214 201774182 T 0.23 −0.56 7.21E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs13412430 201774355 T 0.23 −0.56 7.21E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs10172647 201778950 A 0.23 −0.56 7.29E-06 2 ORC2/intron
rs3125719 29990966 T 0.18 −0.56 7.30E-06 13 MTUS2/intron
c2.201899549.b37p0 201899549 C 0.17 −0.56 7.35E-06 2
rs6445044 171920569 G 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6414541 171920637 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs3923825 171922127 T 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs3924140 171926314 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs4610256 171928021 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6445045 171928400 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs9867872 171928985 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs9868872 171929530 G 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs4380442 171930381 A 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6763764 171931389 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6803181 171932256 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6780871 171932606 G 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs6806070 171932935 C 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs7619745 171933571 A 0.16 −0.56 7.48E-06 3 FNDC3B/intron
rs2016325 66323500 T 0.35 0.56 7.68E-06 7
rs6435066 201766023 G 0.23 −0.56 8.00E-06 2 NIF3L1/intron
rs7917 201768238 T 0.23 −0.56 8.00E-06 2 NIF3L1/missense
rs11894842 201773545 C 0.23 −0.56 8.00E-06 2 NIF3L1/UTR-3 and ORC2/UTR-3
rs10167387 201808618 C 0.23 −0.56 8.00E-06 2 ORC2/Intron
rs68133847 201812251 G 0.23 −0.56 8.00E-06 2 ORC2/Intron
rs11892372 201819483 A 0.23 −0.56 8.00E-06 2 ORC2/Intron
rs3901120 201863530 C 0.23 −0.56 8.00E-06 2 FAM126B/intron
rs16836591 201894943 T 0.23 −0.56 8.00E-06 2 FAM126B/intron
rs10185136 201904301 T 0.23 −0.56 8.00E-06 2 FAM126B/intron
rs10197833 201904466 C 0.23 −0.56 8.00E-06 2 FAM126B/intron
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Table 1 List of top 140 SNPs (p <0.00001) from GWAS analysis that were predictive of triptolide cytotoxicity in HapMap LCLs
(Continued)
rs16842071 201931730 C 0.23 −0.56 8.00E-06 2 FAM126B/intron
rs13410282 201971024 A 0.23 −0.56 8.00E-06 2 CFLAR/UTR-5
rs16836710 201999845 T 0.19 −0.57 8.39E-06 2 CFLAR/intron
rs61457372 70359774 C 0.35 0.56 8.73E-06 17
rs6841405 65067406 G 0.4 0.56 8.86E-06 4 nearest gene (~150 kb down TECRL)
rs7597409 201893188 T 0.23 −0.56 8.97E-06 2 FAM126B/intron
rs12723025 223977519 T 0.073 0.56 9.06E-06 1 TP53BP2/intron
rs6754564 201779932 C 0.16 −0.56 9.69E-06 2 ORC2/Intron
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expression. Multiple SNPs within CFLAR were associated
with expression levels of MTVR1, PIP5K1B and C9orf19/
GLRIP2.
Functional significance of CFLAR splicing SNP
We selected CFLAR for functional validation in our
study on the basis of following observations; i) higher
number of SNPs in CFLAR were associated with the
triptolide cytotoxicity (Tables 1 and 2); ii) CFLAR. SNP-
mRNA pairs associated with triptolide cytotoxicity in-
cluded three CFLAR mRNA probes additionally multiple
SNPs within CFLAR were associated with each 3 mRNA
probes. Majority of the significantly associated SNPs
within CFLAR gene were intronic and occurred in high
LD (Additional file 2: Figure S1). However, one CFLAR
SNP, rs10190751 G >A, was present at the splice junction
of exon 7 (Fig. 2a) and was significantly associated with trip-
tolide cytotoxicity (Fig. 2b). We screened HapMap cell lines
with AA, AG and GG genotype (3 cell lines in each geno-
type group) for long (CFLAR-L), short (CFLAR-S) and raji
(CFLAR-R) forms of CFLAR splice variants. CFLAR-L form
was present in all cell lines irrespective of the genotype
whereas CFLAR-S form was only expressed in cell lines with
at least one G allele (Fig. 3a). Real-time quantification of
CFLAR splice variants showed significant association of AA
genotype with low levels of CFLAR-L; complete absence of
CFLAR-S and higher levels of CFLAR-R form (Fig. 3).
Western blot analysis confirmed the association of C-FLIP
protein isoform levels corresponding to rs10190751 geno-
type and CFLAR mRNA isoforms (Fig. 3c).
SiRNA mediated functional studies on CFLAR
We selected Panc-1 for further investigation for impact
of siRNA mediated transient knockdown of CFLAR on
cellular sensitivity to triptolide. We selected Panc-1 for
further investigation for impact of siRNA mediated tran-
sient knockdown of CFLAR on cellular sensitivity to
triptolide. Panc-1 was selected based on the literature
evidence of efficient use of triptolide in pancreatic can-
cer at pre-clinical and clinical level [Ref] as well asCFLAR being reported as a therapeutic target for tripto-
lide in Pancreatic cancer [ref]. Genotype of Panc-1 for
rs10190751, was identified as GG, therefore all isoform
of CFLAR expressed in this cell line and it makes this
cell line a perfect model to do functional validation for
different isoform. In a pancreatic cancer cell line,
Panc-1, siRNA mediated knockdown resulted in sig-
nificant reduction in the CFLAR-L, CFLAR-S and
CFLAR-R isoforms and significant increase in sensitiv-
ity to, triptolide (Fig. 4a and b).
Over expression of CFLAR-long and short isoform
Since Panc-1 demonstrated change in chemo-sensitivity
in siRNA mediated knockdown of CFLAR, we further
overexpressed CFLAR-L and CFLAR-S forms in Panc-1
cell lines. Transient transfection of most abundant iso-
forms of CFLAR was done in Panc-1 cell line using
pEFA-CFLAR-L and pEF6-V5-CFLAR-L plasmid for
Long and Short form of CFLAR respectively. Compared
to cells transfected with control plasmids the level of
CFLAR protein isoforms were significantly increased
(Fig. 4c). Over-expression CFLAR-L or CFLAR-S iso-
forms resulted in significant decrease in sensitivity for
triptolide, (Fig. 4d).
Discussion
Triptolide is a diterpenoid triepoxide and has been used
in traditional Chinese medicine for years. Poor water
solubility and toxicity has limited its use in clinics, how-
ever recent advances focused on developing triptolide
derivatives with better solubility such as MC002 [22],
omtritolide [23], minnelide [10] etc. are showing promis-
ing advancements especially in pancreatic cancer. The
anticancer activity of triptolide has been associated with
its ability to inhibit various pro-proliferative or anti-
apoptotic factors thereby inducing apoptosis [16]. Tripto-
lide has been implicated in activation of both intrinsic and
extrinsic apoptotic pathways by inducing caspase-8, −9
and 3 as well as by inducing cleavage of PARP [24, 25].
Given the fact that triptolide has a promising potential as
a therapeutic agent, we designed this study to identify the
Table 2 Summary of genes with SNPs significantly associated (p < 0.00001) with triptolide cytotoxicty in HapMAP LCLs
Gene Symbol Gene full name Gene summary (Ref gene) # of SNPs at
p < 0.00001
CFLAR Caspase 8 and FADD-like apoptosis regulator The protein encoded by this gene is a regulator of apoptosis and is structurally similar to caspase-8. However, the
encoded protein lacks caspase activity and appears to be itself cleaved into two peptides by caspase-8. Several transcript
variants encoding different isoforms have been found for this gene, and partial evidence for several more variants exists
45
FAM126B Family With Sequence Similarity 126, Member B 22
PPIL3 Peptidylprolyl isomerase 9cyclophilin)-like 3 This gene encodes a member of the cyclophilin family. Cyclophilins catalyze the cis-trans isomerization of peptidylprolyl
imide bonds in oligopeptides. They have been proposed to act either as catalysts or as molecular chaperones in protein-
folding events. Alternative splicing results in multiple transcript variants. PPIases accelerate the folding of proteins. It catalyzes
the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
7
ZNF532 2
NDUFB3 NADH dehydrogenase (ubiquinone0 1beta
subcomplex,3, 12kD
This gene encodes an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase
(Complex I)which is the first enzyme in the electron transport chain of mitochondria. This protein localizes to the inner
membrane of the mitochondrion as a single-pass membrane protein. Mutations in this gene contribute to mitochondrial
complex 1 deficiency
3
NIF3L1 NIF3 NGG1 interacting factor 3-like
1(S. cerevisiae)
Functions as transcriptional correpressor 11
ORC2 Origin recognition complex subunit 2 The origin recognition complex (ORC) is a highly conserved six subunits protein complex essential for the initiation of the
DNA replication in eukaryotic cells. Studies in yeast demonstrated that ORC binds specifically to origins of replication and
serves as a platform for the assembly of additional initiation factors such as Cdc6 and Mcm proteins. The protein encoded
by this gene is a subunit of the ORC complex. This protein forms a core complex with ORC3,−4, and−5. It also interacts
with CDC45 and MCM10, which are proteins known to be important for the initiation of DNA replication.
20
CLK1 CDC-like kinae 1 This gene encodes a member of the CDC2-like (or LAMMER) family of dual specificity protein kinases. In the nucleus, the
encoded protein phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing, releasing them into the
nucleoplasm. The choice of splice sites during pre-mRNA processing may be regulated by the concentration of transacting fac-
tors, including serine/arginine rich proteins. Therefore, the encoded protein may play an indirect role in governing splice site
selection. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endo-
thelial cells and adenovirus E1A pre-mRNA
1
CSMD1 CUB and Sushi multiple domains 1 1
FNDC3B fibronectin type III domain containing 3B 15
MTUS2 microtubule associated tumor suppressor
candidate 2
Binds microtubules. Together with MAPRE1 may target the microtubule depolymerase KIF2C to the plus-end of microtubules.
May regulate the dynamics of microtubules at their growing distal tip
1
TP53BP2 tumor protein p53 binding protein, 2 This gene encodes a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins. The
protein contains four ankyrin repeats and an SH3 domain involved in protein-protein interactions. It is localized to the
perinuclear region of the cytoplasm, and regulates apoptosis and cell growth through interactions with other regulatory
molecules including members of the p53 family. It plays central role in regulation of apoptosis and cell growth via its
interactions. Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of
proapoptotic genes in vivo. Inhibits the ability of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1
















Table 3 Ingenuity pathway analysis tool mapped the genes identified in gene expression vs. cytotoxicity analysis to 5 networks
ID Molecules in Network Score Focus
Molecules
Top Functions
1 arginase,BCL6,BCR (complex),CXCL9,ERK1/2,Fc gamma receptor,Fcgr3,GCNT2,
Gm-csf,GOT,IFN Beta,IFN type 1,Iga,Ige,IgG1,IgG,IgG2a,IgG2b,Igm,IL13,IL19,IL-2R,IL12
(complex),IL12 (family),IL12RB2,IL2RA,Immunoglobulin,Interferon alpha,JAK1,
myosin-light-chain kinase,PRF1,RAB27A,SLC12A6,TH2 Cytokine,THBD
26 12 Cellular Movement, Inflammatory
Response, Cell-To-Cell Signaling
and Interaction








h4,HOXB6,Hsp90,Ifn,IFN alpha/beta,IFNG,IKK (complex),IL1,Insulin,Jnk,JUN,NFkB (complex),p85
(pik3r),Pka,PKP1,Pro-inflammatory Cytokine,Rac,Ras,Ras homolog,RNA polymerase
II,Rxr,STAT,TCR,TSH,Vegf
18 9 Cancer, Dermatological Diseases
and Conditions, Developmental
Disorder
4 Akt,Ap1,calpain,CCND1,CD3,CDK20,Cg,CLDN11,Collagen type I,Collagen(s),Creb,CSF1,
Cyclin A,Cyclin E,DTX1,Fcer1,GPC3,Hsp27,Ifn gamma,Integrin,LDL,MAP2K1/2,
Mapk,MAPKAPK2,Mek,P38 MAPK,Pdgf (complex),PDGF BB,PI3K (complex),
PLC gamma,Rb,Rock,STAT5a/b,Tgf beta,Tnf (family)
14 7 Cellular Movement, Hematological
System Development and
Function, Immune Cell Trafficking
5 D-xylose 1-dehydrogenase (NADP),DHDH,trans-1,2-dihydrobenzene-1,2-diol dehydrogenase 2 1 Carbohydrate Metabolism
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using LCLs from International HapMap project.
Our results identified a QTL on chromosome 2 consist-
ing of several SNPs with significant association with
triptolide IC50. This region on chromosome 2 included
biologically interesting genes such as CLK1, PPL3, NIF3L1,
CFLAR, NDUFB3, CASP10, CASP8 etc. (Tables 1 and 2)
with important roles in apoptosis and cell cycle regulation
pathways. Of particular interest was significant over-
representation the top most significant SNPs in CFLAR
gene (Caspase 8 and FADD like apoptosis regulator).
CFLAR gene encodes for protein c-FLIP, best-known for
its anti-apoptotic regulatory role by inhibiting TNF-alpha,
FAS-L and TRAIL induced apoptosis [26]. Although most
of the SNPs in CFLAR were intronic, one splicing SNP,Table 4 Top probe and genes with expression levels in LCLs associa
Probe chromosome start Stop
hmm21260-S 12 39215842 3921587
GI_21389558-S 12 128035309 1280353
Hs.390856-S 1 111024040 1110240
Hs.469348-S 2 96793632 9679367
GI_37547236-S 2 109782098 1097821
Hs.128030-S 5 55803569 5580361
GI_37538743-S 7 99411521 9941157
GI_40255097-S 11 26541312 2654136
GI_42660336-S 14 89994713 8999476
GI_41352717-S 12 112017575 1120176
hmm28068-S 2 85500058 8550008
GI_4557282-I 1 100099399 1000994
GI_4504802-S 1 65073667 6507371
hmm35855-S 9 116734605 1167346rs10190751 (3’ splice site of intron 6) was of particular
interest [27]. CFLAR-protein, c-FILP exists in several iso-
forms due to alternate splicing, the most studied forms in-
clude long (C-FLIP-L) and short (C-FLIP-S) isoforms of 55
kD and 26 kD, respectively. CFLAR gene has 14 exons and
inclusion or exclusion of intron 6 or exon 7 regulates the
expression of long, or short or raji forms. CFLAR long
form (CFLAR-L) skips exon 7 and is expressed as a full-
length protein of 480 amino acids. CFLAR short form
(CFLAR-S) includes exon 7 thereby changing the reading
frame, creating an early stop codon, and hence a shorter
isoform with 221 amino acids. C-FLIP-L is composed of
two death effector domains (DEDs) at the amino terminus
and a caspase homologous domain, structurally similar to
caspase 8 and caspase 10 at carboxy terminus. In contrastted with Triptolide LC50
gene Spearman correlation P-value
8 hmm21260 −0.563 7.62E-06
58 FLJ31978 0.554 1.16E-05
89 Hs.390856 −0.553 1.18E-05
7 Hs.469348 −0.531 3.04E-05
47 LOC376934 −0.53 3.20E-05
8 Hs.128030 −0.522 4.33E-05
0 LOC377544 −0.518 5.18E-05
1 MUC15 −0.514 5.91E-05
2 LOC400238 −0.514 5.97E-05
02 DTX1 0.509 7.33E-05
6 hmm28068 −0.509 7.37E-05
40 AGL; GDE −0.507 7.75E-05
6 JAK1; JAK1A 0.505 8.57E-05
54 hmm35855 −0.503 9.02E-05
Table 5 Summary of 3 way integrated analysis of Gene-Expression-SNP and triptolide cytotoxicity (p < 0.0001)
Gene expression
(Gene symbol)
Gene description Association with
total # of SNPs
(p < 0.0001)
Distribution of SNPs (Chr: number of SNPs) Distribution of SNPs on gene (Bold indicates
Maximum number of SNPs on Gene)
AGL (Chr1) Amylo-Alpha-1, 6-Glucosidase, 4-
Alpha-Glucanotransferase
27 Chr2:1 / Chr4:2 / Ch6:2 / Chr16:22 CHST5/ADAT1/GABARAPL2/LRP2/SCGN/
TMEM231
ASCL4 (Chr12) Achaete-Scute Complex-Like 4 24 Chr6:5 / Chr7:1 / Ch9:1 / Chr16:2 / Chr17:3 / Chr18:12 MPG/ASXL3/ATP6V0A1/EEPD1/MPG/NAGLU
C21orf96/RUNX-IT1 (Chr21) RUNX1 Intronic Transcript 1 (Non-
Protein Coding)
3 Chr5:1 / Chr9:1 / Chr13:1 PDZD2
C9orf19/GLIPR2 (Chr9) Glioma Pathogenesis-Related Pro-
tein 2
20 Chr1:2 / Chr2:6 / Chr5, 7, 11 and 14 : 1 each / Chr8:3 / Chr12:2 /
Chr13:3
ARRB1 / CAPN2 / CFLAR/ TP53BP2
CRYGS (Chr3) crystallin, gamma S 41 Chr1:30 Chr2 and Chr6: 3 each Chr5:2 Chr8, 9 and 14: 1 each CAMTA1
CTSK (Chr1) Cathepsin X 19 Chr1,9 and 16:1 each/ Chr5:6/ Chr7, 10 and 17: 2 each/ Chr14: 4
each
CRISPLD2/FHAD1/IDE/PTPRD/RBFOX3/SNX6/SP4
DTX1 (Chr12) deltex homolog 1 (Drosophila) 31 Chr 6:5 / Chr 9:1 / Chr 14:2 / Chr 21:23 TIAM1
FOXQ1 (Chr6) Forkhead Box Protein Q1 21 Chr 1:6 / Chr 3:10 / Chr 5 and 6:1 each / Chr 16:3 FLYWCH1/GNG4/PARK2
GABARAPL1 (Chr12) GABA(A) Receptor-Associated
Protein-Like 1
7 Chr 2:5 / Chr 6 and 14:1 each STRN3
JAK1 (Chr1) Janus Kinase 1 44 Chr 1:8 / Chr 2, 3, 6 and 10:2 each/ Chr 4, 12 and 13:1 each / Chr
5:12 / Chr 8:3 / Chr 14:10
GPATCH2/ SLC6A15/ TFDP2
MAPKAPK2 (Chr1) Mitogen-Activated Protein Kinase-
Activated Protein Kinase 2
3 Chr11:2 / Chr 5:1 ARRB1/ OPCML
MGC16186 (Chr10) DPY30 Domain Containing 2 10 Chr 4:4 / Chr 7, 9 and 22:1 each / Chr 10:3 MANBA/ MYO18B
MGC16385 (Chr16) CENPB DNA-Binding Domains
Containing 1
18 Chr 4:4 / Chr 5:2 / Chr 17 and 22:1 each / Chr 14:10 AGXT2L1/ GIP / ITPK1/PDE6A
MTND4 (mitochondrial) Mitochondrially Encoded NADH
Dehydrogenase
16 Chr 1:8 / Chr 4, 6, 8, 9 and 14:1 each / Chr 10:3 GNG4/ GPATCH2/ SH2D4B
MTND5 (mitochondrial) Mitochondrially Encoded NADH
Dehydrogenase 5
10 Chr 9 and 10:1 / Chr 14:8 PTGDR / SH2D4B
MTVR1 (Chr11) Mammary Tumor Virus Receptor
Homolog 1
28 Chr 2:23 / Chr 6 and 10:1 each / Chr 7:3 NIF3L1/ C7orf42/ CFLAR/ FAM126B/NIF3L1/
ORC2
MUC15 (Chr11) Mucin 15, Cell Surface Associated 16 Chr 1:8 / Chr 2:2 / Chr 9, 15 and 21:1 each / Chr 11:3 CAPN2/CGNL1/TP53BP2
MXD4 (Chr4) MAX dimerization protein 4 13 Chr 2:3 / Chr 4, 5, 10 and 17:1 each / Chr 9:2 / Chr 16:4 MPG/NPRL3/CCDC46/KANK1/USP34
NADSYN1 (Chr11) NAD Synthetase 1 38 Chr 2:32 / Chr 13:1 / Chr 16:5 ERBB4/ FHAD1/ GPATCH2
PIP5K1B (Chr9) Phosphatidylinositol 4-Phosphate
5-Kinase Type-1 Beta
75 Chr 1:2 / Chr 2: 65 / Chr 6 and 14:1 each / Chr 7:4 / Chr 13:2 NIF3L1/ ABCC4/ CFLAR/ FAM126B/ GPATCH2/
NDUFB3/NIF3L1/ORC2/PPIL3/SMYD3/TSGA14
PODLX2 (Chr3) podocalyxin-like 2 44 Chr 3 and 20:1 each / Chr 11:39 / Chr 11:3 LDLRAD3
ROPN1 (Chr3) Rhophilin Associated Tail Protein 1 7 Chr 1:2 / Chr 3:3 / Chr 4 and 13:1














Table 5 Summary of 3 way integrated analysis of Gene-Expression-SNP and triptolide cytotoxicity (p < 0.0001) (Continued)
TDE1 (Chr20) Tumor Differentially Expressed 1 39 Chr 1:12 / Chr 2, 10and 14:1 each / Chr 3:6 / Chr 5:9 / Chr 8:7 /
Cht 15:2
FHAD1/PPCS/ SMYD3/ZMYND12
TWSG1 (Chr18) Twisted Gastrulation Protein
Homolog 1
8 Chr 2:5 / Chr 6:3 CLK1/ FAM126B/
VIAAT (Chr20) Solute Carrier Family 32 Member 1 55 Chr 6 and 10:4 each / Chr 12:1 / Chr 13: 3 / Chr 14:41 / Chr 16:2 SNX6/ STRN3/ RSU1















Fig. 2 Schematic representation of CFLAR gene and its splice variants. a The schematic of CFLAR gene shows all the exons and the location of
rs10190751 SNP at the 3’splice site of intron 6. Presence or absence of this SNP regulates production of CFLAR-short form (CFLAR-S). Difference
splice variants of CFLAR are also shown along with the isoform specific primer pair’s used in this study. b Box plot showing association of rs10190751
Splicing SNP with Triptolide LC50 in HapMap LCLs. Y-axis is Log 2 Triptolide IC50 and X-axis represents rs10190751 genotype. Box Plots show medians as
a line between boxes representing the first and third quartiles; the whiskers represent the range after excluding outliers. The outliers are defined as data
points that fall outside of the first and third quartiles by more than 1.5-times the interquartile range. Circles falling outside the whiskers represent outliers
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main. Presence of rs10190751 regulates the splicing event
with rs10190751-A allele resulting in lack of expression of
the short form (Fig. 4). In addition to these isoforms re-
cently cFLIP-R forms has been identified in the Raji cells
[27]. Due to intronic insertion; CFLAR-R isoform has a
premature stop codon resulting in a protein with 212
amino acids and like the CFLAR-S isoform lacks caspase
like domain.
Although the characterization of the functional differ-
ences of these isoforms is still ongoing, cell type specific
pro-apoptotic role of CFLAR-L has been reported.
CFLAR-L expression levels are considered critical factor
in determining the balance between apoptotic and pro-
survival signaling. The CFLAR-L has also been shown to
play critical role in autophagy, necroptosis and apoptosis
in T-lymphocytes with CFLAR-L deficiency triggering
severe cell death upon stimulation [28]. In spite of its
major role in regulating death receptor signaling, it has
been shown to be involved in regulation of apoptosis by
several other mechanism including; modulating the
activity of ripoptosome [29] regulation of nectroptosisby preventing caspase 8 activation [30–32], inhibiting
autophagosome formation by interfering with conjuga-
tion of LC3 and in NFkB signaling with its ectopic ex-
pression resulting in NFkB activation [33–35].
Given the important role of CFLAR (CFLIP) as a key
inhibitor of processing and activation of caspase 8; its
prognostic and therapeutic relevance in AML [36] as
well as in development of drug resistance [37] we de-
signed this study to further explore the clinical signifi-
cance of the CFLAR and its genetic variation especially
the splicing SNP (regulating CFLAR-L and CFLAR-S
forms) as biomarker of risk of disease as well as with de-
velopment drug resistance. Our results of siRNA medi-
ated knock down and overexpression of CFLAR in
pancreatic cancer cell lines further provides evidence of
its involvement in chemo-sensitivity to triptolide.
Gene expression levels of JAK1, AGL, and DTX1
genes, all involved in cell-to cell signaling (Additional
file 4: Figure S3) has been associated with triptolide
cytotoxicity analysis. JAK1, Janus Kinase 1 is involved in
interferon-alpha/beta and -gamma signal transduction
pathways and is a critical component of JAK/STAT
Fig. 3 Correlation of rs10190751 genotype with CFLAR splice variants. a Isoform specific amplification of CFLAR splice-variants (CFLAR-L, CFLAR-S and
CFLAR-R) in LCLs with AA, GG and AG genotype for rs10190751. b Real-time-mRNA quantification showing relative levels of CFLAR-L, CFLAR-S and
CFLAR-R isoforms in different genotype groups. Box plots details are same as in figure 2B. c Western blotting showing protein levels of CFLAR-L and
CFLAR-S/R forms in HapMap LCLs with AA, AG or GG genotype for rs10190751
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and is involved in glycogen degradation; DTX1, deltex
homolog 1 is involved in NOTCH signaling pathway
which is a critical for cell fate determination and has
been implicated in several diseases as well as tumorogenesis
[38]. In our integrative exploratory analysis we identified
several biologically interesting gene-SNP-gene-expression
pairs as TIAM1-DTX1, ASXL3: ASCL4, GPATCH2: JAK1,
CAMPTA1-CRYGS, ERBB4-NADSYN1 etc.
In recent years there has been significant evidence
suggesting triptolide mediated inhibition of ATPase ac-
tivity of XPB, thereby by influencing transcription as
well as Nucleotide excision repair [39]. XPB, also known
as ERCC3 is a subunit of transcription factor TFIIH.
Triptolide has been shown to influence gene expression
by globally reducing gene expression although to not to
same extent for all genes by blocking transcription initi-
ation [40, 41]. Antiproliferative effects of triptolide due
to inhibition of XPB/TFIIH has also been shown to
phenocopy JNK-dependent apoptosis phenotype in Dp53deficient wing disc cells in Drosophila [42]. This global
reduction of transcription caused by triptolide, correlates
well with the phenotypes observed in tumour cells and
in inflammation. If we take in account these evidences,
and if the treatment with triptolide, reduce global tran-
scription, cells with reduction of the CFLAR mRNA iso-
forms by the splicing SNP will be even more sensitive,
since this gene may negatively modulates apoptosis. The
KD and overexpression results using Panc-1 cells incu-
bated with triptolide may also be explained in part by
taking in account a reduction in global transcription
caused by triptolide.
In conclusion, our results identified CFLAR as an im-
portant predictor of triptolide cytotoxicity. Splicing
SNP-rs10190751 regulates production of CFLAR- long
and short isoforms, which are associated with triptolide
cytotoxicity. The central role of anti-apoptotic protein c-
FLIP (CFLAR product) in regulating death receptor sig-
naling points to the fact that this splicing SNP might of
importance to other chemotherapeutic agents. Up-
Fig. 4 Impact of siRNA mediated knockdown or overexpression of CFLAR isoforms on Triptolide sensitivity in Panc-1 cancer cell lines. a Impact of
siRNA medicated knockdown of CFLAR on mRNA expression levels of CFLAR-L, CFLAR-S and CFLAR-R isoforms b Impact of siRNA medicated
knockdown of CFLAR on cellular cytotoxicity to Triptolide. c Western blot showing over expression of CFLAR-L and CLFAR-S isoforms as compared to
cells transfected to control plasmids. d Impact of overexpression of CFLAR-L and CFLAR-S isoforms in cellular sensitivity to Triptolide
Chauhan et al. BMC Genomics  (2015) 16:483 Page 15 of 17regulation of c-FLIP has been associated with poor clin-
ical outcome and thus could be reliable prognostic factor
for several types of cancer, however the significance of
CFLAR genetic variation as predictor of therapeutic effi-
cacy has not been explored so far, thus opening up op-
portunities for future studies.
Conclusions
Triptolide being an emerging drug, provides us a reason
to do a genome wide association study to identify spe-
cific genetic polymorphism which may affect triptolide
induced cytotoxicity. We observed significant association
of triptolide IC50 with SNPs located in biological im-
portant genes from apoptotic pathway, such as CFLAR,
PPIL3, caspase 8/10, NfKb and STAT6. CFLAR is an up-
stream regulator of apoptotic pathway. Due to its im-
portant position as a regulator of apoptosis, we validated
its functional role in triptolide induced cytotoxicity inpancreatic cancer cell line. Our finding shows that
CFLAR polymorphism plays important role in cancer
cell death induced by triptolide. Further studies are
needed to predict the therapeutic response in patients.Availability of supporting data
Gene expression data is publically avialble from Gene
Expression Omnibus under submission number series:
GSE6536. Genotype data is avaiable at HapMap.org-re-
lease 23 (www.HapMap.org).Additional files
Additional file 1: Supplementary Notes.
Additional file 2: Figure S1. LD plot generated using Haploview for
chromosome 2 region flanking CFLAR gene in CEU population.
Chauhan et al. BMC Genomics  (2015) 16:483 Page 16 of 17Additional file 3: Figure S2. Genome-wide association study of mRNA
expression with Triptolide cytotoxicity. Y-axis represents -Log 10 (P value)
and X-axis presents chromosomal location.
Additional file 4: Figure S3. Overlapping networks identified by
pathway analysis of genes identified in gene expression analysis with
Triptolide IC50 in HapMap LCLs using Ingenuity pathway analysis (IPA) tool.
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